BioNTech SE Revenue 2019-2021 | BNTX

BioNTech SE annual/quarterly revenue history and growth rate from 2019 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • BioNTech SE revenue for the quarter ending June 30, 2021 was $6.396B, a 13809.64% increase year-over-year.
  • BioNTech SE revenue for the twelve months ending June 30, 2021 was $9.340B, a 8518.51% increase year-over-year.
  • BioNTech SE annual revenue for 2020 was $0.551B, a 353.02% increase from 2019.
  • BioNTech SE annual revenue for 2019 was $0.122B, a 19.28% decline from 2018.
  • BioNTech SE annual revenue for 2018 was $0.151B, a INF% increase from .
BioNTech SE Annual Revenue
(Millions of US $)
2020 $551
2019 $122
2018 $151
BioNTech SE Quarterly Revenue
(Millions of US $)
2021-06-30 $6,396
2021-03-31 $2,470
2020-12-31 $396
2020-09-30 $79
2020-06-30 $46
2020-03-31 $31
2019-09-30 $32
2019-06-30
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $60.067B $0.551B
BioNTech SE is a biotechnology company. It develops and commercializes immunotherapies for cancer and other diseases. BioNTech SE is based in Mainz, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00